HealthInvest 2024

With rapid growth and significant success underpinning a strong return in investor interest for the healthcare sector, IR Department is excited to announce our inaugural HealthInvest 2024 summit, in partnership with Morgans and Stockhead.

This year's event promises to be a compelling experience, featuring presentations from some of the most innovative companies in the industry, including Clarity Pharmaceuticals, Percheron Therapeutics, Imricor Medical Systems, ImpediMed, and Race Oncology. Below we delve into the focus area for each company and how they are making strides in their healthcare fields.

Clarity Pharmaceuticals (ASX: CU6)

Clarity Pharmaceuticals is at the forefront of precision oncology, focusing on developing next-generation radiopharmaceuticals for treating serious diseases. The company’s proprietary SAR Technology is designed to deliver therapeutic isotopes directly to cancer cells, minimising the impact on surrounding healthy tissues. This precise targeting not only enhances treatment efficacy but also significantly reduces side effects, offering a promising outlook for patients with hard-to-treat cancers. One of Clarity’s leading programs is SARTATE™, which targets somatostatin receptors commonly found in neuroendocrine tumours. The company’s approach could potentially transform the way these tumours are diagnosed and treated, improving patient outcomes and quality of life.

Percheron Therapeutics (ASX: PER)

Percheron Therapeutics is making waves in the field of biotechnology with its cutting-edge approach to treating cancer. The company focuses on developing antibody-drug conjugates (ADCs), which combine the targeting capabilities of antibodies with the cell-killing ability of cytotoxic drugs. This innovative approach allows for the direct delivery of potent drugs to cancer cells while sparing healthy tissues, thereby improving safety and efficacy profiles. Percheron’s pipeline includes promising candidates for treating various cancers, including solid tumors and hematological malignancies.

Imricor Medical Systems (ASX: IMR)

Imricor Medical Systems is pioneering the development of MRI-compatible medical devices, focusing on improving the accuracy and safety of cardiac ablation procedures. Traditionally, these procedures have been performed under X-ray guidance, exposing patients and healthcare providers to ionising radiation. Imricor’s breakthrough technology allows for cardiac ablation under real-time MRI guidance, offering superior visualisation of soft tissues and reducing radiation exposure.

ImpediMed (ASX: IPD)

ImpediMed is a medical technology company leading the way in non-invasive solutions for clinical assessment and patient monitoring. The company specialises in bioimpedance spectroscopy (BIS) technology, which measures fluid status and tissue composition with precision. ImpediMed’s flagship product, SOZO®, is a unique device that provides real-time, actionable data to healthcare professionals, helping them to manage fluid levels in patients with conditions such as lymphedema, heart failure, and chronic kidney disease.

Race Oncology (ASX: RAC)

Race Oncology is committed to finding new treatments for cancer by repurposing existing drugs. Its lead asset, Bisantrene, is a small molecule cancer drug with a unique mechanism of action that distinguishes it from other chemotherapy agents. Bisantrene has shown promising activity in clinical trials, particularly for treating acute myeloid leukemia (AML). Beyond AML, Race is exploring Bisantrene potential in other cancers, including breast cancer, due to its ability to target specific cancer cell pathways and overcome drug resistance.

Join us at HealthInvest 2024

Whether you're a professional or retail investor, we invite you to join us at HealthInvest 2024 to gain insights into the cutting-edge developments shaping the future of healthcare.

Visit our website to learn more about our expert presenters and the innovative companies they represent.

If you'd like to be part of this exciting event, please register for free here.